PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDacarbazine
Dacarbazine
Dacarbazine (dacarbazine) is a small molecule pharmaceutical. Dacarbazine was first approved as Dtic-dome on 1982-01-01. It is used to treat fibrosarcoma, hodgkin disease, islet cell carcinoma, medullary carcinoma, and melanoma amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
Dacarbazine (discontinued: Dacarbazine, Dtic-dome)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dacarbazine
Tradename
Company
Number
Date
Products
DTIC-DOMEBayerN-017575 DISCN1982-01-01
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aleve arthritis pain gelANDA2025-12-04
amazon basic care arthritis painANDA2024-05-17
arthritis painANDA2025-10-28
arthritis pain relieverANDA2026-01-29
arthritis pain relievingANDA2025-11-17
arthrotecNew Drug Application2025-08-14
aspercreme arthritisANDA2026-01-12
basic care arthritis painANDA2022-01-06
berkley and jensen arthritis painANDA2023-07-26
biorepair sensitive teethunapproved drug other2017-06-13
Show 124 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
neuroblastomaEFO_0000621D009447—
hodgkin disease—D006689C81
melanoma—D008545—
fibrosarcoma—D005354—
rhabdomyosarcoma—D012208—
islet cell carcinoma—D018273C25.4
medullary carcinoma—D018276—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01A: Alkylating agents
— L01AX: Other alkylating agents in atc
— L01AX04: Dacarbazine
HCPCS
Code
Description
J9130
Dacarbazine, 100 mg
Clinical
Clinical Trials
1185 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_0000515—18823849219413
GliomaD005910EFO_0000520—851021129177
MelanomaD008545——501083913169
Brain neoplasmsD001932EFO_0003833C7159781815138
Central nervous system neoplasmsD016543——4563916110
NeoplasmsD009369—C80644991—106
AstrocytomaD001254EFO_0000271—4641181699
Hodgkin diseaseD006689—C816552631094
LymphomaD008223—C85.91150223786
OligodendrogliomaD009837EFO_0000631—272471256
Show 7 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GliosarcomaD018316——605410—1105
NeuroblastomaD009447EFO_0000621—25316—153
Nervous system neoplasmsD009423——16343—450
RecurrenceD012008——20296—349
SarcomaD012509——14309—248
MedulloblastomaD008527——22171——32
Lung neoplasmsD008175—C34.906222—126
EpendymomaD004806——18101—126
Ewing sarcomaD012512EFO_0000173—13201——26
Neuroendocrine tumorsD018358EFO_1001901D3A.84202—125
Show 43 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RhabdomyosarcomaD012208——1214———18
Breast neoplasmsD001943EFO_0003869C50613——117
Ovarian neoplasmsD010051EFO_0003893C5669———12
Colorectal neoplasmsD015179——210———10
PinealomaD010871——74———10
OsteosarcomaD012516——87———10
Pancreatic neoplasmsD010190EFO_0003860C2539———9
Rhabdoid tumorD018335——74———9
Neuroendocrine carcinomaD018278———8———8
Islet cell adenomaD007516EFO_0007331D13.717———7
Show 100 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MeningiomaD008579EFO_0003098D32.96————6
CraniopharyngiomaD003397——5————5
Subependymal gliomaD018315EFO_1001197—5————5
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.04————4
Blood coagulation disordersD001778EFO_0009314D68.91———34
AdamantinomaD050398——3————3
PhenylketonuriasD010661—E70.03————3
Hemostatic disordersD020141——1———23
Carcinoid tumorD002276—D3A.002————2
Burkitt lymphomaD002051—C83.72————2
Show 38 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Septic shockD012772—A48.3————44
Pressure ulcerD003668—L89————33
ShockD012769—R57.1————22
ChemoradiotherapyD059248——————11
DepressionD003863—F33.9————11
ThrombocytopeniaD013921HP_0001873D69.6————11
HivD006678—O98.7————11
ContraceptionD003267——————11
Snake bitesD012909—T63.0————11
Iridocorneal endothelial syndromeD057129——————11
Show 22 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDacarbazine
INNdacarbazine
Description
Dacarbazine is a monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma. It has a role as an antineoplastic agent, an alkylating agent, a prodrug and a carcinogenic agent. It is a monocarboxylic acid amide, a member of imidazoles and a triazene derivative.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN(C)/N=N/c1[nH]cnc1C(N)=O
Identifiers
PDB—
CAS-ID1185241-28-4
RxCUI—
ChEMBL IDCHEMBL476
ChEBI ID—
PubChem CID2942
DrugBankDB00851
UNII ID7GR28W0FJI (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Cambia – Assertio Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Cambia – Assertio Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Arthrotec – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Diclofenac – Amneal Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Diclofenac – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Keveyis – Strongbridge Biopharma
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Keveyis – Xeris Biopharma Holdings
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Zipsor – Assertio Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Zipsor – Assertio Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Lidocaine – Amneal Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Lidocaine – Amphastar Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 6,902 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arthrotec, Cambia, Capsinac, Clofenax, Dacarbazine, Dicloenac sodium and misoprostol, Diclofenac, Diclofenac epolamine, Diclofenac potassium, Diclofenac potassium for oral solution, Diclofenac sodium, Diclofenac sodium 1.5%, Diclofenac sodium and misoprostol, Diclofenac sodium d/r, Diclofenac sodium delayed release, Diclofenac sodium diclofenac sodium, Diclofenac sodium extended-release, Diclofenac sodium gel, Diclofenac sodium misoprostol, Diclofenac sodium topical sol, Diclofenac sodium topical solution, Diclofenac sodium/misoprostol, Diclogen, Diclosaicin, Diclostream, Diclotral pak, Diclovix m, Diclozor, Dimentho, Fenovar, Flector, Flexipak, Iclofenac cp, Inflatherm, Lefluniclo, Lextol, Licart, Lixofen, Lofena, Orthaphen, Pennsaid, Profinac, Varophen, Venngel ii, Venngel one, Ziclopro, Zipsor, Zorvolex
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
141,922 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use